ArticleCancers2020

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer.

Julie E Bauman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.